Another strategy involves the overexpression of oncogenic fusion genes reported in human BC samples in CD34+ cells from CML with the goal of inducing a blast crisis in vitro. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.